Table 2.

Plasma or serum lipid profiles in control subjects and patients whose HDL antioxidative activities were measured in apoBd plasma or serum, respectively, with the DCF assay

	Plasma				Serum
	Controls	CHD	High TG	High SAA	Controls	High MPO
Number	59	58	37	28	57	30
M/F, n	30/29	54/4**	25/12	19/9	32/25	15/15
TC, mg/dL	165 ± 26	145 ± 29**	262 ± 178**	163 ± 44	188 ± 38	169 ± 46
HDL-C, mg/dL	59 ± 14	43 ± 13**	34 ± 15**	51 ± 17*	60 ± 15	49 ± 16*
LDL-C, mg/dL	94 ± 19	80 ± 23**	115 ± 68*	89 ± 6	112 ± 35	100 ± 41
TG, mg/dL	74 (63–99)	128 (88–170)**	324 (264–1080)**	115 (92–163)*	97 (70–123)	116 (93–146)
sd LDL-C, mg/dL	16 (14–19)	37 (27–44)**	41 (27–63)**	17 (12–27)	25 (18–32)	23 (19–30)
Apo A-I, mg/dL	158 ± 23	152 ± 34	129 ± 45**	148 ± 48	168 ± 29	149 ± 33
Glucose, mg/dL	110 ± 17	103 ± 31	164 ± 80	110 ± 21	92 ± 15	105 ± 23
Insulin μIU/mL	13.2 ± 13.1	15.1 ± 9.5	19.8 ± 12.1	14.1 ± 7.2	8.3 ± 5.1	22.0 ± 13.5
Hs-CRP, mg/L	1.7 ± 1.9	2.4 ± 4.9	7.9 ± 15.1	5.5 ± 4.4	1.3 ± 1.2	2.7 ± 11.6
HDL distribution
Preβ-1, %	8 (6–10)	12 (9–15)**	15 (10–19)**	8 (6–11)	5 (4–7)	5 (4–7)
α-1, %	23 (20–28)	15 (12–19)**	11 (7–17)**	17 (12–21)**	22 (19–25)	20 (16–22)
α-2, %	44 (42–47)	42 (39–45)*	41 (36–44)*	54 (49–61)**	41 (37–44)	40 (39–43)
α-3, %	15 (13–16)	18 (16–20)**	17 (13–23)**	11 (9–15)**	13 (12–15)	15 (13–17)
α-4, %	10 (8–11)	12 (10–14)**	13 (10–16)**	6 (5–9)**	11 (9–12)	12 (10–14)

Data are shown as mean ± SD or median (interquartile range). Differences in values between each group and Controls were tested by Pearson chi-squared test, Student-t test or Mann-Whitney’s U test (*p < 0.05 and **p < 0.01, relative to Controls)